BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,055 filers reported holding BAXTER INTL INC in Q2 2022. The put-call ratio across all filers is 1.57 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $75,529 | -8.4% | 1,986 | +10.3% | 0.01% | 0.0% |
| Q2 2023 | $82,418 | +48.1% | 1,800 | +32.1% | 0.01% | +50.0% |
| Q1 2023 | $55,668 | -13.1% | 1,363 | +9.0% | 0.00% | -20.0% |
| Q4 2022 | $64,093 | +10.5% | 1,251 | +17.6% | 0.01% | -16.7% |
| Q3 2022 | $58,000 | -80.6% | 1,064 | -77.1% | 0.01% | -76.0% |
| Q2 2022 | $299,000 | -12.1% | 4,640 | +6.2% | 0.02% | 0.0% |
| Q1 2022 | $340,000 | -21.3% | 4,371 | -12.8% | 0.02% | 0.0% |
| Q4 2021 | $432,000 | +12.5% | 5,012 | +5.3% | 0.02% | +8.7% |
| Q3 2021 | $384,000 | +2.4% | 4,761 | +2.4% | 0.02% | 0.0% |
| Q2 2021 | $375,000 | +1.6% | 4,648 | +6.5% | 0.02% | -11.5% |
| Q1 2021 | $369,000 | +41.4% | 4,364 | +34.6% | 0.03% | +30.0% |
| Q4 2020 | $261,000 | +8.3% | 3,241 | +8.4% | 0.02% | -4.8% |
| Q3 2020 | $241,000 | +12.1% | 2,989 | +20.0% | 0.02% | 0.0% |
| Q2 2020 | $215,000 | +5.9% | 2,490 | -0.0% | 0.02% | -4.5% |
| Q1 2020 | $203,000 | – | 2,491 | – | 0.02% | – |
| Q4 2019 | $0 | – | 0 | – | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 0 | -100.0% | 0.00% | -100.0% |
| Q2 2019 | $7,000 | -98.7% | 82 | -98.7% | 0.00% | -98.2% |
| Q1 2019 | $534,000 | +15.1% | 6,557 | -6.9% | 0.06% | 0.0% |
| Q4 2018 | $464,000 | +7.2% | 7,042 | +25.7% | 0.06% | -54.9% |
| Q3 2018 | $433,000 | – | 5,603 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |